Research Topics
| Margaret V RagniSummaryAffiliation: University of Pittsburgh Country: USA Publications
| Collaborators
|
Detail Information
Publications
Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infectionM V Ragni
Department of Medicine, University of Pittsburgh Medical Center and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA 15213 4306, USA
J Infect Dis 183:1112-5. 2001..03-1.14; P=.069) and increased with each decade of HCV infection (RR, 2.26; 95% CI, 1.42-3.59; P=.0006) and HIV infection (RR, 2.18; 95% CI, 1.36-3.49; P=.0013). These findings suggest that HIV accelerates HCV disease progression...- Hemophilia gene transfer: comparison with conventional protein replacement therapyMargaret V Ragni
Division Hematology, Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 4606, USA
Semin Thromb Hemost 30:239-47. 2004..This article reviews and compares the risks and benefits of standard protein-based therapy with those of gene transfer, and considers how gene transfer might fit into state-of-the-art management of hemophilia... - Survival of human immunodeficiency virus-infected liver transplant recipientsMargaret V Ragni
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213 4306, USA
J Infect Dis 188:1412-20. 2003..Further prospective studies are warranted... - Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapyM V Ragni
Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
J Infect Dis 180:2027-9. 1999..With discontinuation of HAART, HCV RNA decreased as HIV RNA rebounded. Further study is required to clarify the histopathologic significance of this finding... - Safe passage: a plea for safety in hemophilia gene therapyMargaret V Ragni
Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, and Hemophilia Center of Western PA, Pittsburgh, Pennsylvania 15213-4306, USA
Mol Ther 6:436-40. 2002 - New-generation recombinant factor concentrates: bridge to gene therapyM V Ragni
University of Pittsburgh Medical Center and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA 15213 4306, USA
Haemophilia 7:28-35. 2001..It is likely that improvement in safety and reduction in immunogenicity will require modification not only of antigenic structure but also of the immune response to coagulation proteins... - Use of recombinant factor IX in subjects with haemophilia B undergoing surgeryM V Ragni
University of Pittsburgh School of Medicine, General Clinical Research Center, Hemophilia Center of Western Pennsylvania, Pittsburgh 15213, USA
Haemophilia 8:91-7. 2002..Thus, rFIX was found to be safe and effective in achieving haemostasis in subjects with FIX deficiency undergoing surgery... - Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver diseaseMargaret V Ragni
Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213 4306, USA
Liver Transpl 11:1425-30. 2005..05. In conclusion, pretransplant survival appears shorter in HIV-positive OLTX candidates and is unrelated to severity of liver or HIV disease. Further study is warranted to determine risk factors for poorer pretransplant outcomes... 
Anticoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic anticoagulation: a cost-effectiveness analysis from a U.S. perspectiveAllyson M Pishko
Department of Medicine, Division Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213 4306, USA
Thromb Haemost 108:303-10. 2012..In conclusion, prophylactic LMWH given to decrease cancer-related mortality, with no conventional indication, appears economically reasonable if its suggested mortality benefit is confirmed in future trials...
Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis TrialMargaret V Ragni
University of Pittsburgh Medical Center, Department of Medicine, Division Hematology Oncology, and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA
Expert Rev Hematol 4:495-507. 2011....- Safety of the new generation recombinant factor concentratesKimberly W Schlesinger
Hemophilia Center of Western Pennsylvania, 3636 Boulevard of the Allies, Pittsburgh, PA 15213-4306, USA
Expert Opin Drug Saf 1:213-23. 2002..Despite this, recombinant factors remain the most attractive treatment approach for haemophilia. Future improvement awaits the development of safe and effective gene transfer technology... - Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia AMargaret V Ragni
Department of Medicine, Division of Hematology Oncology and Vascular Medicine Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
Thromb Haemost 109:248-54. 2013..In summary, rhIL-11 increases VWF levels in two of four DDAVP-unresponsive or allergic VWD and F.VIII levels in four of five mild or moderate haemophilia A subjects, suggesting its potential use in treatment of these disorders... - AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia BCatherine S Manno
Department of Pediatrics, University of Pennsylvania and The Children s Hospital of Philadelphia, PA, 19104, USA
Blood 101:2963-72. 2003.... - Impact of HIV on liver fibrosis in men with hepatitis C infection and haemophiliaM V Ragni
Department of Medicine, Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, PA 15213 4306, USA
Haemophilia 17:103-11. 2011..Nearly one-fourth of haemophilic men have Metavir ≥ 3 fibrosis. The odds for developing fibrosis are increased in those with elevated alpha-fetoprotein, increasing age and past HCV treatment... - On the cutting edge: von Willebrand factor propeptide and thrombosisM V Ragni
Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh, and Hemophilia Center of Western PA, Pittsburgh, PA 15213, USA
J Thromb Haemost 4:2553-5. 2006 - Tissue plasminogen activator to prevent central venous access device infections: a systematic review of central venous access catheter thrombosis, infection and thromboprophylaxisM V Ragni
Division Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 4306, USA
Haemophilia 14:30-8. 2008..Clinical trials to evaluate t-PA in CVAD infection prevention are justified... - A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand diseaseM V Ragni
Department of Medicine Hematology Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Haemophilia 14:968-77. 2008..Recombinant IL-11 increases VWF levels in humans with mild VWD, justifying future clinical trials to determine its potential in preventing or reducing bleeding in this patient population... - Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infectionM V Ragni
Department of Medicine, Division Hematology Oncology, University of Pittsburgh Medicine Center, Pittsburgh, PA 15213 4306, USA
Haemophilia 15:552-8. 2009..HIV+ HAART Rx and HIV- did not differ in HCV duration, age at ESLD, age at death or present, overall or AIDS mortality, all P > 0.05. These data suggest that HAART improves ESLD-free survival, approaching that in HIV- men... - Risk factors for inhibitor formation in haemophilia: a prevalent case-control studyM V Ragni
Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 4306, USA
Haemophilia 15:1074-82. 2009..The ideal time to initiate prophylaxis to reduce CNS bleeding and inhibitor formation will require prospective studies... - Viral pathogensM V Ragni
Department of Medicine, Division Hematology Oncology, University of Pittsburgh Medical Center and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA 15213 4306, USA
Haemophilia 16:40-6. 2010..The purpose of this chapter is to provide an update on three clinically significant transfusion-transmitted viral pathogens... - Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagiaMargaret V Ragni
Division Hematology Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Thromb Haemost 106:641-5. 2011..0-13.5). rhIL-11 was well tolerated with grade 1 or less fluid retention, flushing, conjunctival erythema, and local bruising. In summary, rhIL-11 reduces menorrhagia safely and warrants further study... - Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, thrombosis, and atherosclerosis studiesTimothy C Nichols
Department of Medicine, Francis Owen Blood Research Laboratory, University of North Carolina, Chapel Hill, NC 27516, USA
Thrombosis 2010:461238. 2010..The current status of porcine and canine VWD are also reviewed as well as their potential role in future studies of VWF-related disorders of hemostasis and thrombosis... - Pulmonary embolism and spiral computerized tomographic scansMargaret V Ragni
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 4306, USA
Curr Opin Pulm Med 15:430-8. 2009..The purpose of this review is to summarize the state-of-the-art of radiographic pulmonary embolism detection and consider future directions to reduce this significant public health problem... - Association of venous thromboembolism with human immunodeficiency virus and mortality in veteransShawn L Fultz
Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA
Am J Med 116:420-3. 2004 - Progression of HIV in haemophiliaM V Ragni
University of Pittsburgh School of Medicine, PA 15213 4306, USA
Haemophilia 4:601-9. 1998.... - Cumulative risk for AIDS and other HIV outcomes in a cohort of hemophiliacs in western PennsylvaniaM V Ragni
Department of Medicine, University of Pittsburgh School of Medicine, PA
J Acquir Immune Defic Syndr 3:708-13. 1990..01). In conclusion, (a) nearly half of this cohort is estimated to develop AIDS by 7 1/2 years' duration of infection, and (b) older age is associated with significantly shorter time to AIDS and shorter survival once AIDS occurs... - Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis CM E De Vera
Thomas E Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Am J Transplant 6:2983-93. 2006..Hepatitis C is a major cause of graft loss and patient mortality in coinfected patients undergoing LTx... - Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic ratesEnrico M Novelli
Division of Hematology Oncology, University of Pittsburgh Medical Center UPMC, Vascular Medicine Institute VMI, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Am J Hematol 87:326-30. 2012..Our results suggest that TSP1 levels are associated with more VOE, hydroxyurea use and lower rates of hemolysis. High TSP1 concentrations may indicate higher risk of the viscosity/vaso-occlusion phenotype of SCD... - Pulmonary embolism incidence is increasing with use of spiral computed tomographyNicholas A DeMonaco
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
Am J Med 121:611-7. 2008..Pulmonary embolism causes significant morbidity in hospitalized patients, yet few studies have explored the impact of spiral computed tomography (CT) scanning on diagnosis and clinical outcome... - Cost-utility analysis of von Willebrand disease screening in adolescents with menorrhagiaRobert Francis Sidonio
Division of Pediatric Hematology Oncology, Children s Hospital of Pittsburgh University of Pittsburgh Medical Center, Pittsburgh, PA 15201, USA
J Pediatr 157:456-60, 460.e1. 2010..To construct a decision analysis model to evaluate the cost utility of von Willebrand disease (VWD) testing in adolescents with menorrhagia... - Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysisKenneth J Smith
Medicine Hematology Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213 4306, USA
Thromb Haemost 100:447-52. 2008..In conclusion, screening, counselling and prophylactic AC during high-risk periods in female relatives of FVL carriers is an economically favourable strategy... - Factor VIII-pulsed dendritic cells reduce anti-factor VIII antibody formation in the hemophilia A mouse modelMargaret V Ragni
Medicine Hematology Oncology, University of Pittsburgh Medicine Center, Pittsburgh, PA 15213 4306, USA
Exp Hematol 37:744-54. 2009..VIII-pulsed DCre, propagated from bone marrow in the presence of granulocyte-macrophage colony-stimulating factor and transforming growth factor-beta, in achieving F.VIII tolerance... - Genetics of bleeding disorders in womenEnrico M Novelli
Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Semin Thromb Hemost 34:509-19. 2008..The purpose of this article is to review the genetics of inherited bleeding disorders in women, focusing on bleeding manifestations, diagnostic methodologies, and management... - Lack of desmopressin (DDAVP) response in men with hemophilia A following liver transplantationP A Lamont
Department of Medicine, University of Pittsburgh School of Medicine, Division of Hematology and Oncology, Pittsburgh, PA 15213-4306, USA
J Thromb Haemost 3:2259-63. 2005..By contrast, both VWF and FVIII increased in a non-hemophilic transplant recipient after DDAVP. These findings support a model in which intracellular co-localization of FVIII and VWF is necessary for in vivo FVIII secretion after DDAVP... - Bleeding manifestations in males with von Willebrand diseaseO Ziv
Department of Medicine, University of Pittsburgh School of Medicine, The Hemophilia Center of Western Pennsylvania and The Institute of Transfusion Medicine, Pittsburgh, PA 15213-7281, USA
Haemophilia 10:162-8. 2004..The failure to avoid postoperative bleeding and related complications in patients with vWD by taking a personal and family bleeding history constitutes a major public health problem... - Coagulation factor VIIa (recombinant) in nonhemophilic patients requiring neurosurgeryColleen M Culley
Drug Use and Disease State Management DUDSM Program, Department of Pharmacy and Therapeutics, University of Pittsburgh Medical Center UPMC, Pittsburgh, PA 15213, USA
Am J Health Syst Pharm 66:1554-9. 2009..The clinical outcomes, safety, and use of resources associated with the administration of factor VIIa (recombinant) to nonhemophilic patients requiring neurosurgery were evaluated... - Disappearance of inhibitor to factor VIII in HIV-infected hemophiliacs with progression to AIDS or severe ARCM V Ragni
Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania
Transfusion 29:447-9. 1989..The mechanism by which the anti-FVIII inhibitor disappears is not known, but it is likely to be related to a quantitative decline in T4 cell number... - Acquired anti-FVIII inhibitors in childrenR J Moraca
The Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center, PA, USA
Haemophilia 8:28-32. 2002..In conclusion, acquired anti-FVIII inhibitors in children may cause severe bleeding, and remit in the majority after FVIII and/or immunosuppressive therapy... - von Willebrand disease and bleeding in womenM V Ragni
Department of Medicine, University of Pittsburgh School of Medicine, USA, Pittsburgh, Pennsylvania, USA
Haemophilia 5:313-7. 1999..Obtaining a personal and family bleeding history promotes early diagnosis, potentially prevents postoperative bleeding, and improves the health of women with vWD... - Clinical manifestations and management of labor and delivery in women with factor IX deficiencyM Y Yang
Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh School of Medicine, and The Hemophilia Center of Western Pennsylvania, Pittsburgh, PA 15213, USA
Haemophilia 10:483-90. 2004..Postpartum bleeding is common in women with haemophilia B or carriers of haemophilia B, and treatment with factor replacement for at least 4 days of postpartum may prevent bleeding following delivery in such women... - Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusionJerry S Powell
Division of Hematology and Oncology, Suite 3016, UC Davis Cancer Center, University of California at Davis, 4501 X St, Sacramento, CA 95817
Blood 102:2038-45. 2003.... - Liver transplantation in HIV-seropositive individualsMargaret V Ragni
Ann Intern Med 144:223; author reply 223-4. 2006 - CD8(+) T-cell responses to adeno-associated virus capsid in humansFederico Mingozzi
The Children s Hospital of Philadelphia, 3615 Civic Center Boulevard, Philadelphia, Pennsylvania 19104, USA
Nat Med 13:419-22. 2007..In addition, we show that AAV-2 induced human T cells proliferate upon exposure to alternate AAV serotypes, indicating that other serotypes are unlikely to evade capsid-specific immune responses...